A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alberta Health Services
• Collaborators: Amersham Health; The Prostate Cancer Research Foundation of Canada
• Treatments: Cisplatin; Hormones

Criteria

Inclusion Criteria:

• adenocarcinoma of the prostate

• life expectancy > 3 months,

• symptomatic from bone metastases

• radiologic evidence of metastatic bone disease

• stable level of pain control

• >18 years

• ability to complete assessments

• prior treatment (chemo) > 4 weeks previous

• discontinued anti-androgens for > 4 weeks

Exclusion Criteria:

• prior strontium therapy

• previous hemibody RT within 6 weeks

• previous cytotoxic chemotherapy within 4 weeks

• use of bisphosphonate medications within 4 weeks

• change in steroid dose within 4 weeks

• active uncontrolled infection

• impending or present spinal cord compression

• significant neurological disorder

• impending pathological fracture

• severe urinary incontinence